So far, the trials have shown that Efti approximately doubles...

So far, the trials have shown that Efti approximately doubles the OS of Keytruda in head and neck and non small cell lung cancer. It also approximately doubles
the number of patients that respond to Keytruda treatment. And it does this without side effects.
So in combination with Keyruda it is likely worth the same as Ketruda.
But in the other trials Efti is showing efficacy in combination with chemotherapy and other immunotherapies. All without side effects.

It appears likely that in the long run Efti will significantly improve efficacy across a wide range of cancer treatments without side effects and at a low treatment cost and patient inconvenience. Patient quality of life during treatment is also significantly improved on Efti.

Efti also has a unique method of action with no competition in development.

Which is why I keep saying that Efti is a blockbuster in the making beyond Keytruda valuation.

Our current share price is ridiculous relative to our results patent portfolio, trials and pipeline.